Context Therapeutics (CNTX) Consolidated Net Income (2020 - 2026)

Context Therapeutics has disclosed Consolidated Net Income across 7 years of filings, most recently posting -$8.8 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$8.8 million, down 93.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$40.6 million (down 46.9% YoY), and the FY2025 annual result was -$36.3 million, down 35.92% from the prior year.
• Consolidated Net Income came in at -$8.8 million for Q1 2026 at Context Therapeutics, up from -$13.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$2.2 million in Q2 2024 to a low of -$17.5 million in Q3 2024.
• The 5-year median for Consolidated Net Income is -$5.3 million (2023), against an average of -$6.6 million.
• Across the five-year window, Consolidated Net Income surged 57.52% in 2024 and plunged 293.82% in 2025, its largest moves.
• Context Therapeutics' Consolidated Net Income stood at -$3.9 million in 2022, then plunged by 78.58% to -$6.9 million in 2023, then surged by 51.73% to -$3.3 million in 2024, then sank by 292.13% to -$13.1 million in 2025, then jumped by 32.76% to -$8.8 million in 2026.
• The last three Consolidated Net Income figures came in at -$8.8 million (Q1 2026), -$13.1 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.